Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7585)	8/4/2001 9:05:17 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

I posted this on SH and thought it might be of some interest here. Careful examination of the balance sheets and income statements still in my mind adds up to obscuring the earlier shipments. Obviously no revenue was there while a considerable amount of inventory was missing. I have trouble with accepting the prepaid idea but that difference is just about a right number. Inventory: Feb 28/00 677 thousand May 31/00 560 thousand Aug 31/00 768 thousand Average Dioptic labs inventory - 668 (using 700) Productions started late Sept/00 Nov 30/00 1,263 thousand (563 Pennsaid - 700 Dioptic) Feb 28/01 934 thousand (234 Pennsaid - 700 Dioptic) While the 563 Pennsaid above is not a full quarter (Sep-Nov), I'll use it to stay conservative. Feb 28 quarter production - 563 Pennsaid inventory end Nov - 563 Pennsaid inventory end Feb - 234 Pennsaid inventory missing using just the numbers they gave us - 892. Without attempting to assess the number of vials (I did but won't go into it here), I'm estimating direct costs at full production to be around 20%. Using 30% here since they're just starting up, to the 20%, I get a DMX revenue range for this shipment somewhere between $2,973 and $4,460 all Cdn. At any rate, this quarter has another 3 months of production in real life to account for. Wolf